Diltiazem improves left ventricular systolic function following acute myocardial infarction treated with streptokinase

American Journal of Cardiology

Volumn 78, Issue 9, 1996, Pages 1049-1052

  Nicolau, José C ^a   Ramires, José A F ^a   Maggioni, Aldo P ^a   Garzon, Sérgio A C ^a   Pinto, Maria A F V ^a   Silva, Délcio G ^a   Nogueira, Paulo R ^a   Maia, Lilia F N ^a   Vendramini, Pedro ^a   Bassi, Irmo ^a  

^a Instituto de Molestias Cardiovasculares   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; FIBRINOLYTIC AGENT; STREPTOKINASE;

AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLE; TIME; TREATMENT OUTCOME;

AGED; CALCIUM CHANNEL BLOCKERS; DILTIAZEM; DOUBLE-BLIND METHOD; FEMALE; FIBRINOLYTIC AGENTS; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; STREPTOKINASE; SYSTOLE; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 10644252920     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00535-8     Document Type: Article

References (20)

1. Gibson RS. Current status of calcium channel-blocking drugs after Q wave andnon-Q-wave myocardial infarction. Circulation 1989;80(suppl IV):IV-107-IV-119.
2. Yusuf S, Held P, Furberg C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVID-II) and other recent studies. Am J Cardiol 1991;67:1295-1297.
3. Erbel R, Pop T, Meinertz T, Olshausen KV, Treese N, Henrichs KJ, Schuster CJ, Rupprecht HJ, Schlürmann W, Meyer J. Combination of calcium channel blocker and thrombolytic therapy in acute myocardial infarction. Am Heart J 1988;115:529-539.
4. Klein HH, Pich S, Lindert S, Nebendahl K, Warneke G, Kreuzer H. Treatment of reperfusion injury with intracoronary calcium channel antagonists and reduced coronary free calcium concentration in regionally ischemic, reperfused porcine hearts. J Am Coll Cardiol 1989;13:1395-1401.
5. Knabb RM, Rosamond TL, Fox KAA, Sobel BE, Bergmann SR. Enhancement of salvage of reperfused ischemic myocardium by diltiazem. J Am Coll Cardiol 1986;8:861-871.
6. Gibson RS, Boden WE, Theroux P, Strauss HD, Pratt CM, Gheorghiade M, Capone RJ, Crawford MH, Schlant RC, Kleiger RE, Young PM, Schechtman K, Perryman B, Roberts R. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results from a double-blind, randomized, multicenter trial. N Engl J Med 1986;315:423-429.
7. Gibson RS, Young PM, Boden WE, Schechtman K, Roberts R. Prognostic significance and beneficial effect of diltiazem on the incidence of early recurrent ischemia after non-Q-wave myocardial infarction: results from the Multicenter Diltiazem Reinfarction Study. Am J Cardiol 1987;60:203-209.
8. Nicolau JC, Lorga AM, Garzon SAC et al. Clinical and laboratory signs of reperfusion: are they reliable? Int J Cardiol 1989;313-320.
9. TIMI (Thrombolysis in Myocardial Infarction) Study Group. The thrombolysis in myocardial infarction (TIMI) trial: phase I findings. N Engl J Med 1985;312:932-936.
10. Schwartz H, Leiboff RH, Bren GB, Wasserman AG, Katz RJ, Varghese PJ, Sokil AB, Ross AM. Temporal evolution of the human collateral circulation after myocardial infarction. J Am Coll Cardiol 1984;4:1088-1093.
11. Nicolau JC, Pinto MAFV, Nogueira PR, Lorga AM, Jacob JLB, Garzon SAC. Preditores da sobrevida intra-hospitalar em pacientes infartados submetidos à terapêutica fibrinolítica. Arq Bras Cardiol 1993;61:143-147.
12. Nicolau JC, Garzon SAC, Pinto MAFV, Nogueira PR, Lorga AM, Greco OT, Jacob JLB. Acute myocardial infarction treated with intravenous streptokinase: 6-year follow-up. Int J Cardiol 1993;38:253-262.
13. Wilkinson L. Systat: the system for statistics. Evanston: Systat Inc., 1990.
14. Glantz SA. Primer of biostatistics. 3rd ed. New York: McGraw-Hill, 1987.
15. Boden WE, Bough EW, Reichman MJ, Rich VB, Young PM, Korr KS, Shulman RS. Beneficial effects of high-dose diltiazem in patients with persistent effort angina on betablockers and nitrates: a randomized, double blind, placebo-controlled cross-over study. Circulation 1985;71:1197-1205.
16. Wiesfeld ACP, Remme WJ, Look MP, Kruijseen DACM, van Hoogenhuyze DCA. Acute hemodynamic and electrophysiologic effects and safety of high-dose intravenous diltiazem in patients receiving metoprolol. Am J Cardiol 1992;70:997-1003.
17. Mickelson JK, Hoff PT, Homeister JW, Fantone JC, Lucchesi BR. High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury. J Am Coll Cardiol 1993;21:502-510.
18. Marques-Vidal P, Cambou J-P, Evans A, Arveiler D, Luc G, Bingham A, Cambien F. Medical treatment of myocardial infarction in France and Northern Ireland. Eur Heart J 1995;16:348-353.
19. The GUSTO Investigators. An international randomized trial comparing thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
20. Boden WE, Scheldewaert R, Walters AW, Whitehead A, Coltart DJ, Santoni JP, Belgrave G, Starkey IR. Design of a placebo-controlled clinical trial of long-acting diltiazem and aspirin versus aspirin alone in patients receiving thrombolysis with first acute myocardial infarction. Am J Cardiol 1995;75:1120-1123.